Robert Kotin to Genetic Therapy
This is a "connection" page, showing publications Robert Kotin has written about Genetic Therapy.
Connection Strength
1.935
-
Kotin RM, Wright JF. Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene Therapies. Hum Gene Ther. 2019 12; 30(12):1447-1448.
Score: 0.393
-
Kotin RM, Snyder RO. Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. Hum Gene Ther. 2017 04; 28(4):350-360.
Score: 0.327
-
Negrete A, Kotin RM. Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct Genomic Proteomic. 2008 Jul; 7(4):303-11.
Score: 0.179
-
Cecchini S, Negrete A, Kotin RM. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther. 2008 Jun; 15(11):823-30.
Score: 0.175
-
Negrete A, Yang LC, Mendez AF, Levy JR, Kotin RM. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med. 2007 Nov; 9(11):938-48.
Score: 0.170
-
Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, Shoemaker RH, Kotin RM. Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther. 2007 May; 14(10):814-27.
Score: 0.162
-
Yang YW, Kotin RM. Glucose-responsive gene delivery in pancreatic Islet cells via recombinant adeno-associated viral vectors. Pharm Res. 2000 Sep; 17(9):1056-61.
Score: 0.103
-
Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. 1994 Jul; 5(7):793-801.
Score: 0.067
-
Airenne KJ, Hu YC, Kost TA, Smith RH, Kotin RM, Ono C, Matsuura Y, Wang S, Yl?-Herttuala S. Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther. 2013 Apr; 21(4):739-49.
Score: 0.061
-
Barbash IM, Cecchini S, Faranesh AZ, Virag T, Li L, Yang Y, Hoyt RF, Kornegay JN, Bogan JR, Garcia L, Lederman RJ, Kotin RM. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther. 2013 Mar; 20(3):274-82.
Score: 0.058
-
Hsu PY, Kotin RM, Yang YW. Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes. Pharm Res. 2008 Jun; 25(6):1460-8.
Score: 0.044
-
Thorsen F, Afione S, Huszthy PC, Tysnes BB, Svendsen A, Bjerkvig R, Kotin RM, L?nning PE, Hoover F. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. J Gene Med. 2006 Sep; 8(9):1131-40.
Score: 0.039
-
Huszthy PC, Svendsen A, Wilson JM, Kotin RM, L?nning PE, Bjerkvig R, Hoover F. Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts. Hum Gene Ther. 2005 Mar; 16(3):381-92.
Score: 0.035
-
Smith RH, Ding C, Kotin RM. Serum-free production and column purification of adeno-associated virus type 5. J Virol Methods. 2003 Dec; 114(2):115-24.
Score: 0.032
-
Wendtner CM, Nolte A, Mangold E, Buhmann R, Maass G, Chiorini JA, Winnacker EL, Emmerich B, Kotin RM, Hallek M. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 1997 Jul; 4(7):726-35.
Score: 0.021
-
Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y, Ma S, Sharma RB, Gray-Edwards HL, Johnson JA, Johnson AK, Alonso LC, Punzo C, Wagner KR, Maguire CA, Kotin RM, Martin DR, Sena-Esteves M. In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Mol Ther. 2016 08; 24(7):1247-57.
Score: 0.019
-
Le Guiner C, Montus M, Servais L, Cherel Y, Francois V, Thibaud JL, Wary C, Matot B, Larcher T, Guigand L, Dutilleul M, Domenger C, Allais M, Beuvin M, Moraux A, Le Duff J, Devaux M, Jaulin N, Guilbaud M, Latournerie V, Veron P, Boutin S, Leborgne C, Desgue D, Deschamps JY, Moullec S, Fromes Y, Vulin A, Smith RH, Laroudie N, Barnay-Toutain F, Rivi?re C, Bucher S, Le TH, Delaunay N, Gasmi M, Kotin RM, Bonne G, Adjali O, Masurier C, Hogrel JY, Carlier P, Moullier P, Voit T. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther. 2014 Nov; 22(11):1923-35.
Score: 0.017
-
Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H, Asokan A, Samulski RJ, Moullier P, Voit T, Garcia L, Svinartchouk F. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol. 2012 Jun; 86(12):6620-31.
Score: 0.014
-
Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005 Apr 19; 102(16):5820-5.
Score: 0.009
-
Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol. 2002 Aug; 76(16):8446-54.
Score: 0.007